Trends Shaping APAC’s CDMO/CRO Sector

Q1. Could you start by giving us a brief overview of your professional background, particularly focusing on your expertise in the industry?

A business professional with over 15 years of diverse experience in the Life Science industry, specializing in Account Management, Sales & Marketing, Product & Pipeline Management, and Manufacturing sciences. Have hands-on experience in microbial fermentation and mammalian cell culture-based biopharmaceutical manufacturing processes. I have successfully managed a comprehensive portfolio of process chemicals, raw materials, consumables, and contractual services supporting R&D and manufacturing across small and large molecule platforms.

Q2. Which emerging markets or subregions within APAC offer the highest upside potential for early-stage investments, and what factors make them attractive compared to more developed hubs?

India, Indonesia, Vietnam, Taiwan, Philippines are some of the hot segments in the CRO/CDMO space.

Some of the main factors are:

• Cost advantage
• Support from the government towards establishing these industries by making an industry friendly policy
• Diverse scalability options
• End-to end service offerings

Q3. How are leading CDMO/CROs differentiating themselves in biologics and specialty outsourcing across APAC and the Middle East in 2025, and which service segments are scaling fastest?

Focusing on niche segments like mRNA-based therapies, Cell and gene therapy, ADCs

…